HOW TO READ A RESEARCH PAPER (FOR NON-SCIENTISTS)
You will make substantially better decisions about peptide use if you can read and critically evaluate the papers behind them. You do not need a PhD to do this — you need to know which parts matter, which to skim, and what makes a study trustworthy or limited.
1.Finding papers and accessing them
PubMed (pubmed.ncbi.nlm.nih.gov) is the primary database for biomedical research, operated by the National Library of Medicine. Search by compound name, mechanism, or author. The search will return abstracts for all indexed papers — many link to free full text (look for the 'Free PMC article' or 'Free article' labels). For papers behind paywalls, author-provided preprints on ResearchGate or Academia.edu are often freely available.
ClinicalTrials.gov lists registered clinical trials, including ongoing and completed studies. This is essential for understanding what human data exists and is in progress for any compound. A compound with multiple registered Phase II trials is in a very different evidence position than one with only rodent studies — even if the human trial data is not yet published.
Google Scholar indexes papers beyond PubMed including conference proceedings, dissertations, and some non-English-language journals. Useful for broad searches but returns more variable quality than PubMed's biomedical focus. Use both for comprehensive searches on important compounds.
Using PubMed effectively: use the filters sidebar to narrow by species (Human Studies, Animal Studies), study type (Clinical Trial, Systematic Review, Meta-Analysis), and date. A search for 'BPC-157' filtered to 'Clinical Trial' and 'Human' immediately shows you how limited the human clinical data is — a sobering but important clarification of the evidence landscape.
Systematic reviews and meta-analyses aggregate findings across multiple studies and are the most valuable single documents for understanding what a body of literature collectively shows. When one exists for a compound you care about, read it first — it synthesizes the evidence and identifies where findings are consistent vs. contradictory.
2.Reading a paper efficiently
Read in this order: (1) Title and abstract — is this relevant to your question? (2) Discussion/Conclusion section — what did they find? (3) Methods — how did they measure it, and is the study design credible? (4) Results section — only if the previous sections indicate the study is relevant and credible. Most papers can be adequately evaluated without reading the full results section.
The abstract summarizes the study rationale, methods, key findings, and conclusions. Learn to extract three things from any abstract: (1) What population was studied (animals, healthy humans, sick patients)? (2) What dose and duration was used? (3) What outcome was measured, and what was the effect size? If any of these is unclear from the abstract, that alone is informative about the paper's quality.
Sample size (n) is the most important number to look for. A rat study with n=6 per group is almost useless for drawing conclusions — statistical power to detect anything but enormous effects is minimal. A human trial with n=100 per group is meaningful. A meta-analysis aggregating n=1,000+ is much better. Dramatic claims in papers with tiny n are preliminary at best and meaningless at worst.
Effect size matters more than p-value. A p-value tells you whether a result is statistically significant (unlikely to be due to chance). It tells you nothing about whether the effect is clinically meaningful. A drug that reduces pain by 0.5 points on a 100-point scale might have p<0.001 in a large trial — statistically significant, clinically irrelevant. Look for absolute effect sizes and compare them to clinically meaningful thresholds.
Conflict of interest disclosures: check the funding source and author affiliations at the end of most papers. Research funded by the compound manufacturer does not automatically mean the findings are wrong — most pharma-funded research is genuine — but it is context for weighting the conclusions. Studies from entirely independent labs are higher credibility for compound claims than studies from the inventor's institution.
3.What makes a study trustworthy
Randomized controlled trial (RCT) with double-blinding: participants are randomly assigned to treatment or placebo, neither participants nor researchers know who received what. This controls for placebo effects, expectation bias, and selection effects. Most research peptide studies are not RCTs — they are observational, uncontrolled, or animal studies. Understanding what you are reading (controlled vs. uncontrolled, human vs. animal) is the most important interpretive skill.
Replication by independent labs: one study, even a well-designed one, is a finding. Multiple independent research groups replicating the same finding is evidence. BPC-157's rodent literature spans multiple decades, multiple countries, and multiple independent research groups consistently showing the same effects on multiple injury models. That replication matters enormously compared to a single well-designed study from one lab.
Biological plausibility: does the claimed effect fit with known biology? A peptide claiming to repair soft tissue via angiogenesis (BPC-157) fits well with what we know about how wound healing works. A supplement claiming to add 10 lbs of muscle in one week without any known anabolic mechanism should raise immediate skepticism. Research that aligns with established biological mechanisms is more credible than research that requires inventing new biology.
Preprints vs. peer-reviewed publications: preprints (papers posted before peer review, on bioRxiv, medRxiv, etc.) are not yet peer-reviewed and should be treated as preliminary. Peer review is imperfect but it filters out obvious methodological errors and requires authors to address reviewer challenges. Weight peer-reviewed publications over preprints, but recognize that peer review does not guarantee correctness.
Watch for: single lab with no independent replication, impossible consistency of results (no natural variation in biological data), author lists that overlap completely across every paper on the same compound (a group validating its own work), study designs that perfectly align with what the funder would want to show, and statistical gymnastics that appear designed to achieve significance.
4.Translating animal doses to humans
The most common error in interpreting peptide research: applying rodent doses directly to humans. Animal studies use doses that are dramatically higher per body weight than appropriate human doses because smaller animals have higher metabolic rates and different pharmacokinetic parameters. A dose of 10 mg/kg in a rat does not translate to 10 mg/kg in a human.
The Reagan-Shaw formula for body surface area scaling: Human Equivalent Dose (mg/kg) = Animal Dose (mg/kg) × (Animal Km / Human Km). Where Km is the body surface area scaling factor: rat Km = 6, mouse Km = 3, human Km = 37. For a 250g rat dose of 10 mg/kg: HED = 10 × (6/37) = 1.62 mg/kg. For a 70 kg human: HED total dose = 1.62 × 70 = 113 mg. This is why research peptide doses in humans are far lower than what is used in rat studies.
Even after body surface area scaling, animal-to-human dose translation is imperfect for many reasons: species differences in receptor sensitivity, metabolism rate, protein binding, and tissue distribution all affect dose-response relationships in ways that body surface area scaling does not capture. The scaling formula gives you a starting range — human pharmacokinetics studies are needed to refine it.
Population specificity: an animal study using young, healthy male rodents tells you something about that population. Translating those results to elderly humans, women, or people with metabolic conditions requires additional inference. Studies in animal disease models (induced diabetes, induced arthritis, induced gut injury) may translate better to humans with those conditions than to healthy controls.
Practical conclusion: use animal studies as directional evidence and to understand mechanisms, not as precise dosing prescriptions. When human clinical data exists at any level, weight it over animal data. When no human data exists, animal data is valuable context — but extrapolate with explicit acknowledgment of the uncertainty involved.
Sources & Studies
Greenhalgh T., BMJ, 1997
Muttenthaler M. et al., Nat Rev Drug Discov, 2021